Many cancer drugs remain unproven 5 years after accelerated approval, study finds

The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ lives? In a new study, researchers found that most cancer drugs granted accelerated approval do not demonstrate such benefits within…

Related Keywords

United States ,San Diego ,California ,Houston ,Texas ,American ,Edward Cliff ,Jennifer Litton ,Cherie Duvall Jones ,Ezekiel Emanuel ,Md Anderson Cancer Center ,Harvard Medical School ,University Of Pennsylvania ,American Association For Cancer Research ,Drug Administration ,Journal Of The American Medical Association ,American Medical Association ,American Association ,Cancer Research ,Harvard Medical ,Cancer Center ,